Renata Medical has raised $25 million in Series D financing to expand commercialization of its Minima Stent System and advance a broader pipeline of cardiovascular devices designed specifically for children. The financing was led by healthcare investment firm ARCHIMED, with participation from existing investors.
Renata plans to use the proceeds to expand U.S. commercialization of Minima, enter international markets and advance additional pediatric congenital heart disease technologies.
The capital will also support continued collection of clinical evidence as Minima adoption expands across congenital heart programs.
The Minima Stent System is a balloon-expandable growth stent specifically designed for neonates, infants and young children with pulmonary artery stenosis or coarctation of the aorta.
The system received FDA premarket approval in August 2024.
In August 2025, the Centers for Medicare & Medicaid Services granted Minima a New Technology Add-on Payment designation, giving hospitals additional reimbursement support for use of the technology.
Renata said adoption of Minima has exceeded its expectations since commercial launch in 2024.
The company is addressing a longstanding challenge in pediatric cardiovascular medicine, where children have frequently been treated using devices originally designed for adult anatomy.
Renata is developing pediatric-specific technologies intended to accommodate the unique clinical requirements of growing children and potentially reduce the need for repeat interventions.
The company was founded in 2019 and is based in Newport Beach, California.
ARCHIMED manages approximately €9 billion and focuses exclusively on healthcare investments.
KEY QUOTES:
“Adoption of the Minima Stent System has exceeded our expectations since commercial launch in 2024. The support and participation of ARCHIMED is further validation of what we are building and of the growing opportunity to transform care for children with congenital heart disease.”
Dustin Armer, Co-Founder And CEO Of Renata Medical
“Children born with congenital heart defects have too often been treated with devices built for adults and many face repeat procedures simply because their implants cannot grow with them. Having spent much of my career in cardiovascular devices, I have rarely seen a technology address so clearly an unmet need. We are proud to back the Renata team as they scale the business and advance a pipeline of purpose-built pediatric therapies.”
André-Michel Ballester, Managing Partner At ARCHIMED
